Product Detail
- HOME >
- For Researchers >
- Product Search >
- Search Result >
- #10777 Anti-Human Gd-IgA1(KM55) Rat IgG MoAb
Product Search
#10777 Anti-Human Gd-IgA1(KM55) Rat IgG MoAb
- Intended Use：
- Research reagents
- Application：
- IHC
- Package Size1：
- 100 μg
- Package Size2：
- 10 μg
- Note on Application Abbreviations
- IHC:Immunohistochemistry
※ The product indicated as "Research reagents" in the column Intended Use cannot be used
for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
enclosed in the product purchased before use.
Product Overview
Product Overview
| Product Code | 10777 |
|---|---|
| Product Name | Anti-Human Gd-IgA1(KM55) Rat IgG MoAb |
| Maker Name | Immuno-Biological Laboratories Co., Ltd. |
| Intended Use | Research reagents |
| Application | IHC |
| Species | Human |
| Immunizing antigen | Human IgA1 hinge region peptide with GalNAc H-C223PST*PPT*PS*PS*TPPT*PSPS240-NH2(*with GalNAc) |
| Source | Mouse-Rat hybridoma |
| Clone Name | KM55 |
| Subclass | Rat IgG2b |
| Purification Method | Affinity purified with protein A |
| Package Form | Lyophilized product from PBS containing 1 % BSA and 0.05 % NaN3 |
| Storage Condition | 2 ～ 8 ℃ |
| Poisonous and Deleterious Substances | Applicable |
| Cartagena | Not Applicable |
| Package Size 1 | 100 μg |
| Package Size 2 | 10 μg |
| Remarks1 | The commercial use of products without our permission is prohibited. Please make sure to contact us and obtain permission. |
Product Description
Product Description
Galactose-deficient IgA1 (Gd-IgA1) attracts a lot of attentions as a critical effector molecule in the pathogenesis and progression of IgA nephropathy (IgAN) in recent studies. It has been suggested that several O-link glycans modified regions exist in the heavy chain hinge region of human IgA1 molecule andGd-IgA1 circulates in blood stream of the patients with the pathological condition of IgAN. The deposition of Gd-IgA1 in glomeruli is considered to be involved in IgAN (Multi-hit Hypothesis of Gd-IgA1). The measuring system using snail (Helix aspersa; HAA) lectin that is extracted from snail and Gd-IgA1 ELISA (Code: 27600 Gd-IgA1 (Galactose-deficient IgA1) Assay Kit using this antibody (KM55) have been used in numerous studies and it has been suggested that serum level of Gd-IgA1 in patients with IgAN is signicficantly elevated compare with the level of healthy subject or patients with renal disease other than IgAN in such studies. In addition, this antibody (KM55) can detect Gd-IgA1 in tissue by IHC technique differently from the feature of HAA lectin and it has been revealed that Gd-IgA1 specicillay exists in glomeruli of the patients of IgAN from the studies using this antibody. It has been expected that clinical significance of Gd-IgA1 wil be revealed by further studies using this antibody.
References
References
- Aberrant Gut Microbiome Contributes to Barrier Dysfunction, Inflammation and Local Immune Responses in IgA Nephropathy. Tang Y et al. Kidney Blood Press Res. 2023 Mar 6;48(1):261–76.PMID: 36878203
- cnm-positive Streptococcus mutans is associated with galactose-deficient IgA in patients with IgA nephropathy. Suzuki H et al. PLoS One. 2023 Mar 2;18(3):e0282367.PMID: 36862654
- Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy. Fukao Y et al. J Clin Med. 2022 Jun 2;11(11):3173.PMID: 35683557
- Proceedings of 16th International Symposium on IgA Nephropathy IgA Nephropathy 2021, 21–23 September 2021 (Virtual).
IgAN: A South-Asian perspective. Page 5.
What biomarkers are on the horizon that may help risk stratify patients with IgAN? Page 45.
Clinical significance of intensity of glomerular galactose-deficient IgA1 deposition in IgA nephropathy. Page 69.
Relevance of serum Gd-IgA1 levels in South Asian IgAN- prospective longitudinal cohort (GRACE-IgANI). Page 74.PMID: N/A - Glomerulonephritis with severe nephrotic syndrome induced by immune complexes composed of galactose-deficient IgA1 in primary Sjögren's syndrome: a case report. Nishioka R et al. BMC Nephrol. 2021 Mar 25;22(1):108.PMID: 33765955
- Utility of glomerular Gd-IgA1 staining for indistinguishable cases of IgA nephropathy or Alport syndrome. Ishiko S et al. Clin Exp Nephrol. 2021 Mar 20.PMID: 33743099
- KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis. Zhang M et al. Nephron. 2021;145(3):225-237.PMID: 33596564
- Association Between Galactose-Deficient IgA1 Derived From the Tonsils and Recurrence of IgA Nephropathy in Patients Who Underwent Kidney Transplantation. Kawabe M et al. Front Immunol. 2020 Sep 3;11:2068.PMID: 33013875
- Glomerular galactose-deficient IgA1 expression analysis in pediatric patients with glomerular diseases. Ishiko S et al. Sci Rep. 2020 Aug 20;10(1):14026.PMID: 32820208
- A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy. Sugiyama M et al. PLoS One. 2020 Apr 23;15(4):e0232194.PMID: 32324811
- Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy. Wang M et al. Kidney Int Rep. 2019 Nov 6;5(2):165-172.PMID: 32043030
- Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy. Zhang K et al. Kidney Blood Press Res. 2019;44(5):1196-1206.PMID: 31574506
- TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Makita Y et al. Kidney Int. 2020 Feb;97(2):340-349. Epub 2019 Sep 5.PMID: 31748116
- Galactose deficient IgA1 (GD-IgA1) in skin and serum from patients with skin-limited and systemic IgA Vasculitis. Neufeld M et al. J Am Acad Dermatol. 2019 Mar 19. pii: S0190-9622(19)30443-8.PMID: 30902725
- Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1. Yamasaki K et al. Monoclon Antib Immunodiagn Immunother. 2018 Dec;37(6):252-256.PMID: 30570353
- Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. Wada Y et al. PLoS One. 2018 Nov 2;13(11):e0206865.PMID: 30388165
- Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Suzuki H. Clin Exp Nephrol. 2019 Jan;23(1):26-31.PMID: 29740706
- IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Suzuki H et al. Kidney Int. 2018 Mar;93(3):700-705.PMID: 29329643
- Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Yasutake J et al. Nephrol Dial Transplant. 2015 Aug;30(8):1315-21.PMID: 26109484
Note: Retrieve by PMID number in displayed by abstract: http://www.ncbi.nlm.nih.gov
FAQ
FAQ
-
Q.What is the recommended concentration of this antibody for use? -
A.It is 100μg/mL. -
Q.I am considering to conduct immunohistochemistry. How many prepalates can be stained with 100ug?
-
A.KM55 is 100ug/1mL.
Usually, 0.1-0.2mL/preparate is used. This means 5-10 prepalates can be stained. -
Q.I am struggling for staining using this antibody. Can you recommend any method for IHC?
-
A.Please refer to the method written in this article.
-
Q.How much is approx. normal IgA in blood?
-
A.Total IgA is approx 1-4mg/mL in blood.
-
Q.How much is approx. normal Gd-IgA in blood?
-
A.As it is approx 1,000 ng/mL in blood, more than 200 fold dilution is recommended for measurement.
-
Q.Where the antibody (Anti-Gd-IgA1(KM55) rat IgG) recognize?
-
-
Q.According to the data sheet of the antibody (KM55), immunogen activation treatment is required when performing immunohistochemical staining (IHC) using KM55 with formalin fixed paraffin embedded tissues.
Why is the treatment required? -
A.The targeted antigen might be masked by the fixation process in immunohistochemical staining.
For avoiding such masking effects, immunogen activation (enzymatic treatment or heat treatment) is required for exposing the targeted antigen.
Subtilisin A treatment is recommended for IHC using the antibody (KM55).
Related Materials
Related Materials
Narrowed Search
Keyword Search
